Signatera ctDNA dynamics are both predictive and prognostic in neoadjuvant TNBC. Lead time up to 30 months between Signatera positivity and radiographic recurrence. AUSTIN, Texas, April 11, 2022...

Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), an international, Fortune 300 automotive retailer with 202 dealerships located in the U.S. and U.K., today announced that senior...

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer,...

Allogeneic, off-the-shelf CAR-T therapy with CD19/CD7 dual-directed CAR shows promising early results in patients with r/r B-ALL PALO ALTO, Calif. and SUZHOU, China, April 8, 2022 /PRNewswire/ --...

- Combining onvansertib with the PARP inhibitor (PARPi) olaparib led to statistically significant survival benefits compared to treatment with either agent alone in PARPi-resistant ovarian cancer...

Trial evaluates onvansertib in combination with abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) patients showing initial abiraterone resistance by rising PSA...

~ New diacylglycerol kinase assay panel provides researchers for the first time with ten new lipid kinase targets ~ ~ New systems biology approach enhances preclinical characterization of the...

-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden -- -- Generally well-tolerated with most AEs Grade 1 or 2, supporting continued dose escalation -- --...

Results from Phase 1 Dose Escalation Study of Tegavivint in Patients with Desmoid Tumors to Be Featured as in a Poster Presentation on April 12, 2022 HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion...

Data to be presented at the 2022 AACR annual meeting highlights the unique nature of post-chemotherapy derived gene expression signatures in stratifying patient outcomes IRVING, Texas, April 8,...